Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Down 81.5% in March

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 899,445 shares, a decline of 81.5% from the February 26th total of 4,865,346 shares. Approximately 22.2% of the shares of the stock are sold short. Based on an average trading volume of 1,570,480 shares, the days-to-cover ratio is currently 0.6 days. Based on an average trading volume of 1,570,480 shares, the days-to-cover ratio is currently 0.6 days. Approximately 22.2% of the shares of the stock are sold short.

Avalon GloboCare Stock Down 7.1%

Shares of ALBT opened at $0.58 on Wednesday. Avalon GloboCare has a 52-week low of $0.42 and a 52-week high of $6.03. The company has a market capitalization of $2.45 million, a PE ratio of -0.16 and a beta of -0.23. The stock has a fifty day simple moving average of $0.80 and a two-hundred day simple moving average of $1.49.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.